Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Arcturus Therapeutics Holdings Inc. Common Stock

ARCT

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

Last trade $7.98
Day change -$0.33 (-3.97%)
Day range $7.71 – $8.73
Volume 229,975
Market cap $240M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$239.52M
Price / earnings
—
Price / book
1.42×
Price / sales
7.85×
EV / sales
1.79×
EV / EBITDA
-0.59×

Profitability

Earnings per share
-$3.03
Return on assets
-40.52%
Return on equity
-51.71%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
6.68×
Quick ratio
6.68×
Cash ratio
6.52×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$62.52M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ARCT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$18.3M$2.96M$2.06M$7.2M$17.15M$28.3M$29.38M$22.77M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$18.3M$2.96M$2.06M$7.2M$17.15M$28.3M$29.38M$22.77M
Selling, general and administrative$10.48M$10.99M$9.47M$14.03M$10.4M$10.34M$11.32M$12.38M
Research and development$17M$17.52M$21.53M$24.48M$23.27M$29.58M$34.89M$43.78M
Total operating expenses$27.48M$28.5M$30.99M$38.5M$33.66M$39.92M$46.21M$56.16M
Operating income-$9.19M-$25.55M-$28.93M-$31.31M-$16.51M-$11.62M-$16.83M-$33.39M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$7.41M-$23.79M-$26.96M-$29.08M-$13.45M-$9.18M-$14.08M-$30.01M
Income taxes$0$0$0-$4K$0$4K$0-$4K
Net income-$7.41M-$23.79M-$26.96M-$29.08M-$13.45M-$9.18M-$14.08M-$30.01M
Net income attributable to common shareholders-$7.41M-$23.79M-$26.96M-$29.08M-$13.45M-$9.18M-$14.08M-$30.01M
EBITDA-$8.58M-$24.9M-$28.27M-$30.63M-$15.75M-$10.84M-$16.03M-$32.58M
Basic earnings per share-$0.26-$0.84-$0.95-$1.03-$0.49-$0.34-$0.52-$1.11
Diluted earnings per share-$0.26-$0.84-$0.95-$1.03-$0.49-$0.34-$0.52-$1.11

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) reported a quarterly loss of $0.26 per share, beating consensus estimates of $0.60 loss by 56.67%, with revenues of $18.3 million exceeding estimates by 116.10%. The stock has gained 77.3% year-to-date, significantly outperforming the S&P 500's 12.3% gain. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

GlobeNewswire Inc.

mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and More

The global mRNA therapeutics market (excluding COVID-19 applications) is projected to grow from USD 201 million in 2026 to USD 9.98 billion by 2035, with a 63% CAGR. Growth is driven by expanding oncology and rare disease pipelines, advances in lipid nanoparticle delivery, and strategic partnerships. However, challenges include tissue-selective delivery limitations, repeat-dose tolerability concerns, and regulatory complexities. Moderna and BioNTech dominate with approximately 70% of pipeline activity.

The Motley Fool

These Are the Only 3 Stocks That Cathie Wood Bought Last Week

Cathie Wood's Ark Invest made surprisingly few purchases last week, buying shares in only three companies: Figma, Arcturus Therapeutics, and 10x Genomics. Despite significant declines from their highs, Wood sees value in these growth-stage companies across design software, biotech, and genomics sectors.

The Motley Fool

Cathie Wood Goes Shopping: 3 Stocks She Just Bought

Cathie Wood of Ark Invest purchased shares of Robinhood Markets, Netflix, and Arcturus Therapeutics on Wednesday, taking advantage of recent stock price dips and seeing potential growth opportunities in these companies.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.